CUE
Cue Biopharma
22.50$
-2.7%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -371.4% | -601.8% | -569.8% | -375.8% | -225.6% | -572.8% | -1,941.1% | -115.6% | -419.9% | -4.9% | -192.4% | -368.2% | -132.9% | |
| 40.8% | 46.7% | 49.4% | 32.4% | 26.3% | -15.1% | 209.5% | 26.9% | 27.7% | 6.6% | 10.0% | 0.5% | 7.1% | |
| 98.7% | 113.8% | 113.3% | 66.0% | 47.5% | 99.1% | 317.8% | 42.8% | 71.3% | 2.8% | 0.8% | 302.6% | 69.1% | |
| 11.7% | -35.5% | -16.0% | -93.2% | -38.1% | -57.2% | 433.3% | 100.4% | -168.3% | -20.4% | -118.4% | 211.1% | 4.8% | |
| 0.0% | 0.0% | 3.2% | 0.4% | 0.0% | 0.1% | 35.6% | 0.9% | 0.0% | 0.0% | 2.1% | 0.0% | 0.3% | |
| 238.1% | – | -3.2% | -0.4% | 2.9% | -0.1% | -35.6% | -0.9% | -314.9% | 32.0% | -2.1% | – | – | |
| – | – | – | – | -30.0% | -63.4% | -237.5% | -33.9% | -46.5% | -6.8% | 0.0% | 0.0% | -6.6% | |
| 218.5% | 262.6% | 137.1% | -37.6% | 294.4% | -59.1% | -237.5% | 602.5% | 0.0% | 43.3% | 5.4% | 381.1% | 105.7% | |
| 85.2% | -339.2% | -435.9% | -413.8% | 71.7% | -632.0% | -2,214.3% | 486.0% | -734.8% | 70.3% | -189.2% | 12.9% | -26.8% | |
| -371.4% | -601.8% | -573.0% | -376.2% | -225.6% | -573.0% | -1,976.7% | -116.5% | -419.9% | -4.9% | -194.6% | -368.2% | -133.2% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.